Skip to content

unani medicine for treatment of women suffering from depression around menopause

Effect of Majoon Najjah in perimenopausal depression - "An open Labelled study

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/035069
Enrollment
30
Registered
2021-07-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N958- Other specified menopausal and perimenopausal disorders

Interventions

Intervention1: majoon najjah: 5 gm Majoon will be administered orally twice daily for 8 weeks. Control Intervention1: single arm: not applicable

Sponsors

Kouser Fathima Firdose
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Females who are currently physically well and between 40 and 65 years of age 2. Current DSM-IV diagnosis of depression disorder 3. Able to give informed consent 4. Perimenopausal as determined by symptom profile on the Stages of Reproductive Aging Workshop and gonadal hormonal profile

Exclusion criteria

Exclusion criteria: 1. Known abnormalities in the hypothalamic-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, breast pathology, undiagnosed vaginal bleeding or abnormal Pap smear results in the previous 2 years. 2. Patients with H/O any significant unstable medical illness such as epilepsy and diabetes, hypertension or known active cardiac, renal or liver disease;malignancy or the presence of illness causing immobilisation. 3. Patients receiving treatment for depression including antidepressant medications, electroconvulsive therapy (ECT) / Transcranial Magnetic Stimulation (TMS), formal psychotherapy or counselling, within the past 6 months. 4. Patients experiencing severe melancholia, neurovegetative symptoms or current suicidality necessitating acute hospitalisation or intensive psychiatric treatment. 5. Patients with psychotic symptoms or past history of severe mental illness including schizophrenia, and bipolar disorder. 6. Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including tibolone or use of phytoestrogen supplements as powder or tablet.

Design outcomes

Primary

MeasureTime frame
Meno D scoreTimepoint: 4 weeks

Secondary

MeasureTime frame
meno dTimepoint: 8 weeks

Countries

India

Contacts

Public ContactKouser Fathima Firdose
kouser2fathima@gmail.com09743730208

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026